<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2007-06-30" updated="2020-01-02">
  <drugbank-id primary="true">DB01344</drugbank-id>
  <drugbank-id>DB06658</drugbank-id>
  <name>Tolevamer</name>
  <description>Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, HIV.</description>
  <cas-number>28210-41-5</cas-number>
  <unii>ZSL2FB6GXN</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Chris Ho, Jugminder Chawla, Hitesh R. Bhagat, "Polystyrene sulfonate polymer tablets, their preparation and use." U.S. Patent US20080299198, issued December 04, 2008.</synthesis-reference>
  <indication>Used to treat abnormally high potassium levels.</indication>
  <pharmacodynamics>Polystyrene sulfonate affects the exchange of sodium and potassium in the body. Polystyrene sulfonate is used to treat high levels of potassium in the blood, also called hyperkalemia. It is a potassium-binding ion-exchange resin that can be administered orally (25 grams in 20% sorbitol) or rectally (50 grams in 20% sorbitol).</pharmacodynamics>
  <mechanism-of-action>Polystyrene sulfonate, which is not absorbed, binds excess potassium, carrying it out of the body. The indigestible potassium polystryene sulfonate complex is excreted with the faeces, preventing the absorption of potassium into the blood stream. Hence, the serum potassium level decreases.</mechanism-of-action>
  <toxicity>Overdose symptoms may include confusion, irritability, trouble thinking or concentrating, muscle weakness, or trouble breathing.</toxicity>
  <metabolism>none</metabolism>
  <absorption>Not absorbed following oral administration.</absorption>
  <half-life>none</half-life>
  <protein-binding/>
  <route-of-elimination>Feces.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002567</drugbank-id>
      <name>Tolevamer calcium</name>
      <unii>HUI2S00793</unii>
      <cas-number>37286-92-3</cas-number>
      <inchikey/>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT002496</drugbank-id>
      <name>Tolevamer potassium sodium</name>
      <unii>4A5OM7PI18</unii>
      <cas-number>1011713-07-7</cas-number>
      <inchikey/>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT000840</drugbank-id>
      <name>Tolevamer sodium</name>
      <unii>1699G8679Z</unii>
      <cas-number>9080-79-9</cas-number>
      <inchikey/>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">poly(styrene-4-sulfonic acid)</synonym>
    <synonym language="english" coder="">Polystyrene sulfonate</synonym>
    <synonym language="english" coder="">Polystyrene sulfonic acid</synonym>
    <synonym language="english" coder="">polystyrenesulfonic acid</synonym>
    <synonym language="english" coder="inn">Tolevamer</synonym>
  </synonyms>
  <products>
    <product>
      <name>K-exit Poudre</name>
      <labeller>Omega Laboratories Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00765252</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral; Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kayexalate</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0024-1075</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1958-01-08</started-marketing-on>
      <ended-marketing-on>2013-04-04</ended-marketing-on>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4.1 meq/1g</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>NDA011287</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kayexalate</name>
      <labeller>Covis Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>24987-075</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-15</started-marketing-on>
      <ended-marketing-on>2018-06-30</ended-marketing-on>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4.1 meq/1g</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>NDA011287</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kayexalate</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02026961</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1961-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>1 g</strength>
      <route>Oral; Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kayexalate</name>
      <labeller>Concordia Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>59212-075</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-15</started-marketing-on>
      <ended-marketing-on>2018-06-30</ended-marketing-on>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4.1 meq/1g</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>NDA011287</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kionex</name>
      <labeller>Paddock Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0574-2004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-02-01</started-marketing-on>
      <ended-marketing-on>2018-07-31</ended-marketing-on>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4.1 meq/1g</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA040029</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kionex</name>
      <labeller>Paddock Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0574-2002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>15 g/60mL</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA040028</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Odan-sodium Polystyrene Sulfonate</name>
      <labeller>Odan Laboratories Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02473941</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength/>
      <route>Oral; Rectal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Odan-sodium Polystyrene Sulfonate</name>
      <labeller>Odan Laboratories Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02473968</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Oral; Rectal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-sodium Polystyrene Sulfonate Oral Suspension</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02261650</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-12-07</started-marketing-on>
      <ended-marketing-on>2010-11-25</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-sodium Polystyrene Sulfonate Powder</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02261677</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-12-07</started-marketing-on>
      <ended-marketing-on>2014-02-10</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral; Rectal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PHL-sodium Polystyrene Sulfonate Retention Enema</name>
      <labeller>Pharmel Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02261669</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-12-07</started-marketing-on>
      <ended-marketing-on>2010-11-25</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Resonium Calcium</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02017741</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral; Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>Roxane Laboratories Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0054-0165</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-08-03</started-marketing-on>
      <ended-marketing-on>2008-11-10</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength>15 g/60mL</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA089049</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>KVK-Tech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10702-036</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>1 g/1g</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA040905</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>Epic Pharma, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>42806-013</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4.1 meq/1g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202333</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>PuraCap Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>24658-760</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4.1 meq/1g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202333</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>Marlex Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>10135-146</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4.1 meq/1g</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA204071</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>Cmp Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>46287-006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-12-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>15 g/60mL</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA087859</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>Trigen Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>13811-656</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>4.1 meq/1g</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA206815</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>Belcher Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>62250-660</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4.1 meq/1g</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA205727</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>Sunrise Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>11534-166</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4.1 meq/1g</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA204071</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4439</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-12-08</started-marketing-on>
      <ended-marketing-on>2008-06-30</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength>15 g/60mL</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA089049</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>Eci Pharmaceuticals Llc</labeller>
      <ndc-id/>
      <ndc-product-code>51293-831</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4.1 meq/1g</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA090313</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>ATLANTIC BIOLOGICALS CORP</labeller>
      <ndc-id/>
      <ndc-product-code>17856-1136</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>1 g/1g</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA040905</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>Atlantic Biologicals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>17856-0831</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4.1 meq/1g</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA090313</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-7353</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>15 g/60mL</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA087859</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>Major</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6041</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-18</started-marketing-on>
      <ended-marketing-on>2018-08-09</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength>1 g/1g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA040905</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>Exact Rx, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42808-500</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-01</started-marketing-on>
      <ended-marketing-on>2017-08-31</ended-marketing-on>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4.1 meq/1g</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA090313</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>Leading Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>69315-205</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-25</started-marketing-on>
      <ended-marketing-on>2018-08-27</ended-marketing-on>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4.1 meq/1g</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA204071</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>Atlantic Biologicals Corps.</labeller>
      <ndc-id/>
      <ndc-product-code>17856-0036</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>1 g/1g</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA040905</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>Lohxa</labeller>
      <ndc-id/>
      <ndc-product-code>70166-712</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>4.1 meq/1g</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA090313</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>Paddock Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0574-2003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>15 g/60mL</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA090590</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>West-Ward Pharmaceuticals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0054-0379</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>15 g/60mL</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA089049</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Polystyrene Sulfonate</name>
      <labeller>Cmp Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>46287-012</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>1 g/1g</strength>
      <route>Oral; Rectal</route>
      <fda-application-number>ANDA089910</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solystat</name>
      <labeller>Pendopharm Division Of Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00769533</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>2019-07-30</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Solystat</name>
      <labeller>Pendopharm Division Of Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00755338</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral; Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Solystat</name>
      <labeller>Pendopharm Division Of Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00769541</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sps Suspension 15gm/60ml</name>
      <labeller>Carolina Medical Products Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00722456</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on>1999-07-26</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Oral; Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Resonium A</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Sorbisterit</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Kayexalate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Kayexalate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Kionex</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Kayexalate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Kionex</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Resonium Calcium</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Kayexalate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Solystat</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Solystat</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>PHL-sodium Polystyrene Sulfonate Oral Suspension</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>PHL-sodium Polystyrene Sulfonate Retention Enema</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>PHL-sodium Polystyrene Sulfonate Powder</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Sps Suspension 15gm/60ml</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>K-exit Poudre</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Solystat</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Odan-sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
    <mixture>
      <name>Odan-sodium Polystyrene Sulfonate</name>
      <ingredients>Tolevamer</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Bayer Healthcare</name>
      <url>http://www.bayerhealthcare.com</url>
    </packager>
    <packager>
      <name>Carolina Medical Products Co.</name>
      <url>http://www.carolinamedical.com</url>
    </packager>
    <packager>
      <name>KVK-Tech Inc.</name>
      <url>http://www.kvktech.com</url>
    </packager>
    <packager>
      <name>Major Pharmaceuticals</name>
      <url>http://www.majorpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Medisca Inc.</name>
      <url>http://www.medisca.com</url>
    </packager>
    <packager>
      <name>Paddock Labs</name>
      <url>http://www.paddocklabs.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Sanofi-Aventis Inc.</name>
      <url>http://www.sanofi-aventis.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Pms-Sod Polystyr Sulf (120 Ml) 30 g/enm Retention Enema</description>
      <cost currency="USD">15.36</cost>
      <unit>enema</unit>
    </price>
    <price>
      <description>Pms-Sodium Polystyrene Sulf. 250 mg/ml Suspension</description>
      <cost currency="USD">0.13</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Pms-Sodium Polystyrene Sulf. Powder</description>
      <cost currency="USD">0.15</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Kayexalate Powder</description>
      <cost currency="USD">0.2</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Sodium Polystyrene Sulfonate  Powder</description>
      <cost currency="USD">0.31</cost>
      <unit>gm</unit>
    </price>
    <price>
      <description>Kalexate powder</description>
      <cost currency="USD">0.39</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Sodium polystyrene sulf powder</description>
      <cost currency="USD">0.39</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Kionex powder</description>
      <cost currency="USD">0.44</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Kionex  Powder</description>
      <cost currency="USD">0.46</cost>
      <unit>gm</unit>
    </price>
    <price>
      <description>Sod poly sulfonate powder</description>
      <cost currency="USD">0.69</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Kayexalate powder</description>
      <cost currency="USD">0.86</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Kayexalate  Powder</description>
      <cost currency="USD">0.9</cost>
      <unit>gm</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Acids</category>
      <mesh-id>D000143</mesh-id>
    </category>
    <category>
      <category>Acids, Noncarboxylic</category>
      <mesh-id>D000148</mesh-id>
    </category>
    <category>
      <category>Benzene Derivatives</category>
      <mesh-id>D001555</mesh-id>
    </category>
    <category>
      <category>Benzylidene Compounds</category>
      <mesh-id>D001597</mesh-id>
    </category>
    <category>
      <category>Cation Exchange Resins</category>
      <mesh-id>D002411</mesh-id>
    </category>
    <category>
      <category>Chelating Agents</category>
      <mesh-id>D002614</mesh-id>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Drugs for Treatment of Hyperkalemia and Hyperphosphatemia</category>
      <mesh-id/>
    </category>
    <category>
      <category>Ion Exchange Resins</category>
      <mesh-id>D007475</mesh-id>
    </category>
    <category>
      <category>Laboratory Chemicals</category>
      <mesh-id>D019995</mesh-id>
    </category>
    <category>
      <category>Macromolecular Substances</category>
      <mesh-id>D046911</mesh-id>
    </category>
    <category>
      <category>Plastics</category>
      <mesh-id>D010969</mesh-id>
    </category>
    <category>
      <category>Polymers</category>
      <mesh-id>D011108</mesh-id>
    </category>
    <category>
      <category>Polystyrene Sulfonates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Potassium Binder</category>
      <mesh-id/>
    </category>
    <category>
      <category>Potassium Ion Exchange Activity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Potassium-removing Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Sequestering Agents</category>
      <mesh-id>D064449</mesh-id>
    </category>
    <category>
      <category>Styrene</category>
      <mesh-id>D020058</mesh-id>
    </category>
    <category>
      <category>Styrenes</category>
      <mesh-id>D013343</mesh-id>
    </category>
    <category>
      <category>Sulfur Acids</category>
      <mesh-id>D013456</mesh-id>
    </category>
    <category>
      <category>Sulfur Compounds</category>
      <mesh-id>D013457</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Powder</form>
      <route>Oral; Rectal</route>
      <strength>1 g</strength>
    </dosage>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral; Rectal</route>
      <strength>4.1 meq/1g</strength>
    </dosage>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral; Rectal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Rectal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Oral; Rectal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Oral</route>
      <strength>1 g/1g</strength>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Oral; Rectal</route>
      <strength>1 g/1g</strength>
    </dosage>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral</route>
      <strength>4.1 meq/1g</strength>
    </dosage>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral; Rectal</route>
      <strength>1 g/1g</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Oral; Rectal</route>
      <strength>15 g/60mL</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Oral; Rectal</route>
      <strength>4.1 meq/1g</strength>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Oral; Rectal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Oral; Rectal</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="V03AE01">
      <level code="V03AE">Drugs for treatment of hyperkalemia and hyperphosphatemia</level>
      <level code="V03A">ALL OTHER THERAPEUTIC PRODUCTS</level>
      <level code="V03">ALL OTHER THERAPEUTIC PRODUCTS</level>
      <level code="V">VARIOUS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>40:18.18</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <patents/>
  <food-interactions>
    <food-interaction>Avoid calcium, magnesium and potassium.</food-interaction>
    <food-interaction>Take on an empty stomach.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB01370</drugbank-id>
      <name>Aluminium</name>
      <description>The risk or severity of adverse effects can be increased when Tolevamer is combined with Aluminium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>The risk or severity of adverse effects can be increased when Tolevamer is combined with Magnesium oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01390</drugbank-id>
      <name>Sodium bicarbonate</name>
      <description>The risk or severity of adverse effects can be increased when Tolevamer is combined with Sodium bicarbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06723</drugbank-id>
      <name>Aluminum hydroxide</name>
      <description>The risk or severity of adverse effects can be increased when Tolevamer is combined with Aluminum hydroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06724</drugbank-id>
      <name>Calcium carbonate</name>
      <description>The risk or severity of adverse effects can be increased when Tolevamer is combined with Calcium carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08938</drugbank-id>
      <name>Magaldrate</name>
      <description>The risk or severity of adverse effects can be increased when Tolevamer is combined with Magaldrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>The risk or severity of adverse effects can be increased when Tolevamer is combined with Magnesium hydroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>The risk or severity of adverse effects can be increased when Tolevamer is combined with Magnesium trisilicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>The risk or severity of adverse effects can be increased when Tolevamer is combined with Magnesium carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13209</drugbank-id>
      <name>Bismuth subnitrate</name>
      <description>The risk or severity of adverse effects can be increased when Tolevamer is combined with Bismuth subnitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13249</drugbank-id>
      <name>Magnesium silicate</name>
      <description>The risk or severity of adverse effects can be increased when Tolevamer is combined with Magnesium silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13280</drugbank-id>
      <name>Aluminium acetoacetate</name>
      <description>The risk or severity of adverse effects can be increased when Tolevamer is combined with Aluminium acetoacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13322</drugbank-id>
      <name>Hydrotalcite</name>
      <description>The risk or severity of adverse effects can be increased when Tolevamer is combined with Hydrotalcite.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13486</drugbank-id>
      <name>Magnesium peroxide</name>
      <description>The risk or severity of adverse effects can be increased when Tolevamer is combined with Magnesium peroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13595</drugbank-id>
      <name>Almasilate</name>
      <description>The risk or severity of adverse effects can be increased when Tolevamer is combined with Almasilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13626</drugbank-id>
      <name>Aluminium glycinate</name>
      <description>The risk or severity of adverse effects can be increased when Tolevamer is combined with Aluminium glycinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13650</drugbank-id>
      <name>Aloglutamol</name>
      <description>The risk or severity of adverse effects can be increased when Tolevamer is combined with Aloglutamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13829</drugbank-id>
      <name>Calcium silicate</name>
      <description>The risk or severity of adverse effects can be increased when Tolevamer is combined with Calcium silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14517</drugbank-id>
      <name>Aluminium phosphate</name>
      <description>The risk or severity of adverse effects can be increased when Tolevamer is combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00024</drugbank-id>
      <name>Thyrotropin alfa</name>
      <description>Tolevamer can cause a decrease in the absorption of Thyrotropin alfa resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>Tolevamer can cause a decrease in the absorption of Liothyronine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00451</drugbank-id>
      <name>Levothyroxine</name>
      <description>Tolevamer can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01583</drugbank-id>
      <name>Liotrix</name>
      <description>Tolevamer can cause a decrease in the absorption of Liotrix resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03604</drugbank-id>
      <name>Tiratricol</name>
      <description>Tolevamer can cause a decrease in the absorption of Tiratricol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09100</drugbank-id>
      <name>Thyroid, porcine</name>
      <description>Tolevamer can cause a decrease in the absorption of Thyroid, porcine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Digoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Acetyldigitoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Deslanoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Ouabain.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Digitoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12843</drugbank-id>
      <name>Oleandrin</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Oleandrin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13240</drugbank-id>
      <name>Cymarin</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Cymarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13307</drugbank-id>
      <name>Proscillaridin</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Proscillaridin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13401</drugbank-id>
      <name>Metildigoxin</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Metildigoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13467</drugbank-id>
      <name>Lanatoside C</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Lanatoside C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13537</drugbank-id>
      <name>Gitoformate</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Gitoformate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Acetyldigoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13756</drugbank-id>
      <name>Peruvoside</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Peruvoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The risk or severity of adverse effects can be increased when Meloxicam is combined with Tolevamer.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>The absorption of Lithium cation can be decreased when combined with Tolevamer.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14507</drugbank-id>
      <name>Lithium citrate</name>
      <description>The absorption of Lithium citrate can be decreased when combined with Tolevamer.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14509</drugbank-id>
      <name>Lithium carbonate</name>
      <description>The absorption of Lithium carbonate can be decreased when combined with Tolevamer.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14506</drugbank-id>
      <name>Lithium hydroxide</name>
      <description>The absorption of Lithium hydroxide can be decreased when combined with Tolevamer.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>The therapeutic efficacy of Tolevamer can be decreased when used in combination with Cimetidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00585</drugbank-id>
      <name>Nizatidine</name>
      <description>The therapeutic efficacy of Tolevamer can be decreased when used in combination with Nizatidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The therapeutic efficacy of Tolevamer can be decreased when used in combination with Ranitidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00927</drugbank-id>
      <name>Famotidine</name>
      <description>The therapeutic efficacy of Tolevamer can be decreased when used in combination with Famotidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00940</drugbank-id>
      <name>Methantheline</name>
      <description>The therapeutic efficacy of Tolevamer can be decreased when used in combination with Methantheline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08805</drugbank-id>
      <name>Metiamide</name>
      <description>The therapeutic efficacy of Tolevamer can be decreased when used in combination with Metiamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08806</drugbank-id>
      <name>Roxatidine acetate</name>
      <description>The therapeutic efficacy of Tolevamer can be decreased when used in combination with Roxatidine acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12770</drugbank-id>
      <name>Lafutidine</name>
      <description>The therapeutic efficacy of Tolevamer can be decreased when used in combination with Lafutidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12884</drugbank-id>
      <name>Lavoltidine</name>
      <description>The therapeutic efficacy of Tolevamer can be decreased when used in combination with Lavoltidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13760</drugbank-id>
      <name>Niperotidine</name>
      <description>The therapeutic efficacy of Tolevamer can be decreased when used in combination with Niperotidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>The therapeutic efficacy of Tolevamer can be decreased when used in combination with Pantoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>The therapeutic efficacy of Tolevamer can be decreased when used in combination with Omeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00448</drugbank-id>
      <name>Lansoprazole</name>
      <description>The therapeutic efficacy of Tolevamer can be decreased when used in combination with Lansoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00736</drugbank-id>
      <name>Esomeprazole</name>
      <description>The therapeutic efficacy of Tolevamer can be decreased when used in combination with Esomeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01129</drugbank-id>
      <name>Rabeprazole</name>
      <description>The therapeutic efficacy of Tolevamer can be decreased when used in combination with Rabeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05351</drugbank-id>
      <name>Dexlansoprazole</name>
      <description>The therapeutic efficacy of Tolevamer can be decreased when used in combination with Dexlansoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13762</drugbank-id>
      <name>Dexrabeprazole</name>
      <description>The therapeutic efficacy of Tolevamer can be decreased when used in combination with Dexrabeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15246</drugbank-id>
      <name>Salvianolic acid A</name>
      <description>The therapeutic efficacy of Tolevamer can be decreased when used in combination with Salvianolic acid A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09139</drugbank-id>
      <name>Technetium Tc-99m oxidronate</name>
      <description>Tolevamer may decrease effectiveness of Technetium Tc-99m oxidronate as a diagnostic agent.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>2089</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>4028</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>53278</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46507832</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164749386</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Polystyrene_sulfonate</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004816</id>
      <name>Potassium</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17124</ref-id>
            <pubmed-id>20798253</pubmed-id>
            <citation>Watson M, Abbott KC, Yuan CM: Damned if you do, damned if you don't: potassium binding resins in hyperkalemia. Clin J Am Soc Nephrol. 2010 Oct;5(10):1723-6. doi: 10.2215/CJN.03700410. Epub 2010 Aug 26.</citation>
          </article>
          <article>
            <ref-id>A17125</ref-id>
            <pubmed-id>20167700</pubmed-id>
            <citation>Sterns RH, Rojas M, Bernstein P, Chennupati S: Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol. 2010 May;21(5):733-5. doi: 10.1681/ASN.2010010079. Epub 2010 Feb 18.</citation>
          </article>
          <article>
            <ref-id>A17126</ref-id>
            <pubmed-id>10630266</pubmed-id>
            <citation>Hoffman RS, Stringer JA, Feinberg RS, Goldfrank LR: Comparative efficacy of thallium adsorption by activated charcoal, prussian blue, and sodium polystyrene sulfonate. J Toxicol Clin Toxicol. 1999;37(7):833-7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>